Brought to you by 
Ligand buys Metabasis for cash and CVRs
05 May 2015
Executive Summary
Ligand Pharmaceuticals is acquiring fellow public company Metabasis Therapeutics (mainly focused on metabolic disorders and liver diseases) for $3.2mm in cash up front, less Metabasis' estimated net liabilities (about $1.3mm) and an undisclosed amount that will be put into the stockholders' representative's fund.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ligand buys Metabasis for cash and CVRs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice